Quarterly report pursuant to Section 13 or 15(d)

Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables)

v3.22.2.2
Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables)
3 Months Ended
Sep. 30, 2022
Notes Tables  
Schedule of the Consolidated Changes in Equity

Consolidated Changes in Equity (amounts in thousands)

    

Bio-Techne Shareholders    

    

    

  

Accumulated

Additional

Other

Common Stock

Paid-in

Retained

Comprehensive

Noncontrolling

Shares

Amount

Capital

Earnings

Income(Loss)

Interest  

Total

Balances at June 30, 2022

 

39,160

392

653,657

1,122,921

(75,200)

(759)

1,701,011

Net earnings

 

-

-

 

-

 

89,555

 

-

 

179

 

89,734

Other comprehensive loss

 

-

-

 

-

 

-

 

(16,762)

 

0

 

(16,762)

Reclassification of cumulative translation adjustment for Eminence to non-operating income

-

-

-

-

152

(33)

119

Elimination of noncontrolling equity interest from sale of Eminence

 

-

 

-

 

-

 

-

 

-

 

613

 

613

Share repurchases

 

(55)

 

(1)

 

-

 

(19,561)

 

-

 

-

 

(19,562)

Common stock issued for exercise of options

 

107

 

1

 

9,422

 

(11,428)

 

-

 

-

 

(2,005)

Common stock issued for restricted stock awards

 

11

-

 

-

 

(6,427)

 

-

 

-

 

(6,427)

Cash dividends

 

-

-

 

-

 

(12,545)

 

-

 

-

 

(12,545)

Stock-based compensation expense

 

-

 

-

 

14,364

 

-

 

-

 

-

 

14,364

Common stock issued to employee stock purchase plan

 

9

-

 

2,517

 

-

 

-

 

-

 

2,517

Employee stock purchase plan expense

-

-

97

-

-

-

97

Balances at September 30, 2022

 

39,232

$

392

$

680,057

$

1,162,515

$

(91,810)

$

-

$

1,751,154

    

Bio-Techne Shareholders

    

    

  

Accumulated

Additional

Other

Common Stock

Paid-in

Retained

Comprehensive

Noncontrolling

Shares

Amount

Capital

Earnings

Income(Loss)

Interest  

Total

Balances at June 30, 2021

 

38,955

$

390

$

534,411

$

1,085,461

$

(57,291)

$

8,263

$

1,571,234

Net earnings

69,615

(634)

68,981

Other comprehensive income (loss)

 

 

  

 

  

 

(6,925)

 

(39)

 

(6,964)

Common stock issued for exercise of options

 

295

 

3

 

36,345

 

(13,481)

 

  

 

  

 

22,867

Common stock issued for restricted stock awards

 

20

 

0

 

0

 

(9,765)

 

  

 

  

 

(9,765)

Cash dividends

 

 

  

 

(12,493)

 

 

  

 

(12,493)

Stock-based compensation expense

 

 

11,396

 

 

  

 

  

 

11,396

Common stock issued to employee stock purchase plan

 

3

 

0

 

1,358

 

 

  

 

  

 

1,358

Employee stock purchase plan expense

 

 

341

 

 

  

 

  

 

341

Balances at September 30, 2021

 

39,273

$

393

$

583,851

$

1,119,337

$

(64,216)

$

7,590

$

1,646,955

Schedule of each component of other comprehensive income (loss)

Unrealized

Gains

Foreign 

(Losses) on

Currency

Derivative

Translation 

    

Instruments

    

Adjustments

    

Total

Balance as of June 30, 2022

$

8,069

$

(83,269)

$

(75,200)

Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne

 

4,376

 

(21,457)

 

(17,081)

Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(1)

 

319

319

Reclassification of cumulative translation adjustment for Eminence to non-operating income, net of taxes, attributable to Bio-Techne

152

152

Balance as of September 30, 2022(2)

$

12,764

$

(104,574)

$

(91,810)

Unrealized

Gains

Foreign 

(Losses) on

Currency

Derivative

Translation 

    

Instruments

    

Adjustments

    

Total

Balance as of June 30, 2021 attributable to Bio-Techne

$

(6,193)

$

(51,098)

$

(57,291)

Other comprehensive income (loss), net of tax before reclassifications, attributable to Bio-Techne

 

84

 

(8,607)

 

(8,523)

Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(1)

 

1,598

 

 

1,598

Balance as of September 30, 2021 (2)

$

(4,511)

$

(59,705)

$

(64,216)

(1)

Gains (losses) on the interest swap are reclassified into interest expense as payments on the derivative agreement are made. The Company reclassified ($417) to interest expense and recorded a related tax benefit of $98 during the quarter ended September 30, 2022. The Company reclassified ($2,091) to interest expense and a related tax benefit of $493 during the quarter ended September 30, 2021.

(2)

The Company had a net deferred tax liability of $3,921 and a net deferred tax benefit of $1,391 included in the accumulated other comprehensive income loss as of September 30,  2022 and 2021, respectively.